Life Sciences Tools and Services
Company Overview of MaRS Innovation
MaRS Innovation operates as a commercialization agent for the intellectual properties in the areas of therapeutics, medical device, diagnostic imaging, information, communications, and manufacturing and clean technologies to the inventors in Canada. The company has strategic partnerships with GlaxoSmithKline Inc.; CML HealthCare Inc.; Baxter International Inc.; and Pfizer Inc. MaRS Innovation was incorporated in 2008 and is based in Toronto, Canada.
101 College Street
Toronto, ON M5G 1L7
Founded in 2008
Key Executives for MaRS Innovation
Chief Executive Officer, President and Director
Chief Financial Officer and Director
Secretary, Executive Assistant of Chief Executive Officer, Executive Assistant of President and Director
Director of Human Resources
Director of Commercialization
Compensation as of Fiscal Year 2014.
MaRS Innovation Key Developments
Encycle Therapeutics Inc. Announces Partnership with MaRS Innovation to Develop Molecule to Tackle Inflammatory Bowel Disease
Nov 10 14
Encycle Therapeutics Inc. in partnership with MaRS Innovation which is involved in the inflammatory process in a number of diseases, most notably for inflammatory bowel disease. To support and advance this molecule, Encycle Therapeutics is collaboratively partnering with the Institute for Research in Immunology and Cancer - Commercialization of Research (IRICoR), the Université de Montréal (UdeM) and MaRS Innovation. The agreement brings a significant investment to fund Encycle Therapeutics' development work, giving IRICoR an equity position and expanding MaRS Innovation's equity stake. Cumulatively, Encycle Therapeutics has secured more than $2.5 million to advance its drug development platform. The partnership will fund and deploy a number of experienced medicinal chemists at UdeM's Institute for Research in Immunology and Cancer (IRIC) to optimize Encycle Therapeutics' lead molecule. Additional studies will be conducted at the biopharmacy platform of the Faculty of Pharmacy of the UdeM, while Encycle Therapeutics conducts other project-related activities, including pre-clinical efficacy studies.
Johnson & Johnson Innovation, Janssen Inc. Announce New Collaborations with NEOMED and MaRS Innovation
Dec 10 13
Johnson & Johnson Innovation and its affiliate Janssen Inc. in Canada announced new collaborations with two Canadian early-stage drug technology development centers, Montreal-based NEOMED and Toronto-based MaRS Innovation, to identify and advance promising bio/pharmaceutical technologies that have the potential to impact human health. Through these collaborations, technical experts from the Johnson & Johnson Innovation Center in Boston, Massachusetts will work with NEOMED and MaRS Innovation to identify investment opportunities emerging from well-validated scientific research discoveries within their communities of academic institutions and biotechnology companies.
MaRS Innovation Presents at BioJapan 2013 World Business Forum, Oct-09-2013
Sep 25 13
MaRS Innovation Presents at BioJapan 2013 World Business Forum, Oct-09-2013 . Venue: Pacifico Yokohama, Yokohama, Japan.
Similar Private Companies By Industry
Recent Private Companies Transactions
Most Searched Private Companies
Sponsored Financial Commentaries